Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly Total Non-Current Liabilities of $4.8 million in Q1 2026, down 13.23% quarter-over-quarter from $5.5 million in Q4 2025, and down 48.23% on a YoY basis from $9.2 million in Q1 2025.
Prothena Corp Public (PRTA) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Prothena Corp Public's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $4.8 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 48.23% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (down 48.23% YoY), while the FY2025 annual figure was $5.5 million, down 53.03% from the prior year.
- Total Non-Current Liabilities was $4.8 million for Q1 2026 at Prothena Corp Public, down from $5.5 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $106.0 million in Q1 2022 to a low of $4.8 million in Q1 2026.
- Historically, Total Non-Current Liabilities has averaged $50.2 million across 5 years, with a median of $67.4 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities climbed 7.25% in 2022, then plunged 88.14% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $85.8 million in 2022, then dropped by 8.99% to $78.1 million in 2023, then plunged by 85.05% to $11.7 million in 2024, then slumped by 53.03% to $5.5 million in 2025, then slipped by 13.23% to $4.8 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $4.8 million (Q1 2026), $5.5 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 4.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.76 Mn |
| Dec 31, 2025 | 5.49 Mn |
| Sep 30, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.93 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 11.68 Mn |
| Sep 30, 2024 | 14.47 Mn |
| Jun 30, 2024 | 16.90 Mn |
| Mar 31, 2024 | 77.53 Mn |
| Dec 31, 2023 | 78.13 Mn |
| Sep 30, 2023 | 76.32 Mn |
| Jun 30, 2023 | 67.41 Mn |
| Mar 31, 2023 | 85.29 Mn |
| Dec 31, 2022 | 85.85 Mn |
| Sep 30, 2022 | 99.19 Mn |
| Jun 30, 2022 | 102.18 Mn |
| Mar 31, 2022 | 106.03 Mn |
| Dec 31, 2021 | 109.87 Mn |
| Sep 30, 2021 | 113.03 Mn |
| Jun 30, 2021 | 95.27 Mn |